The Items Predicting Non-Remission after 6 Months of Treatment of Patients with Generalized Anxiety Disorder Covered the Eysenck Neuroticism Components of Anxiety, Interpersonal Sensitivity and Depression

By  

Psychotherapy and Psychosomatics, Vol. 85, Iss. 4, 2016-05 ,pp. : 229-230

Karger

Access to resources Recommend Favorite

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

By van Baardewijk M.   Vis P. M. J.   Einarson T. R.  

Current Medical Research and Opinion, Vol. 21, Iss. 8, 2005-08 ,pp. : 1271-1280

Informa Healthcare

Access to resources Recommend Favorite

Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases

By Wang Junling   Liu Xianchen   Mullins C. Daniel  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1303-1313

Informa Healthcare

Access to resources Recommend Favorite

Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability

By Montgomery Stuart   Emir Birol   Haswell Hannah   Prieto Rita  

Current Medical Research and Opinion, Vol. 29, Iss. 10, 2013-10 ,pp. : 1223-1230

Informa Healthcare

Access to resources Recommend Favorite

Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes

By Shi Lizheng   Juarez Rodrigo   Hackworth Jodi   Edgell Eric T.   Haro Josep Maria   Vieta Eduard   Tohen Mauricio F.  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 961-966

Informa Healthcare

Access to resources Recommend Favorite